Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: Insights from the RAVEL Trial

European Heart Journal

Volumn 25, Issue 2, 2004, Pages 107-112

  Abizaid, Alexandre ^a,k   Costa, Marco A ^b   Bianchard, Didier ^c   Albertal, Mariano ^a   Eltchaninoff, Hélèn ^d   Guagliumi, Giulio ^e   Geert Jan, Laarman ^f   Abizaid, Andrea S ^a   Sousa, Amanda G M R ^a   Wuelfert, Egon ^g   Wietze, Lindeboom ^h   Sousa, J Eduardo ^a   Serruys, Patrick W ⁱ   Morice, Marie Claude ^j  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^c Clinique Saint Gatien   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e OSPEDALI RIUNITI   (Italy)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^h CARDIALYSIS   (Netherlands)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j INSTITUT HOSPITALIER JACQUES CARTIER   (France)

^k NONE   (Brazil)

more..

Author keywords

Diabetes; Drug eluting stents; Restenosis; Sirolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; CORONARY STENT; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; RESTENOSIS; REVASCULARIZATION;

CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETIC ANGIOPATHIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; STENTS; TUNICA INTIMA;

EID: 9144226193     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.11.002     Document Type: Article

References (16)

1. Carrozza JP Jr, Kuntz RE, Fishman RF et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-9.
2. Stein B, Weintraub WS, Gebhart SP et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
3. Detre KM, Guo P, Holubkov R et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-40.
4. Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
5. Abizaid A, Kornowski R, Mintz GS et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-9.
6. Van Bette E, Perie M, Braune D et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002;40:410-7.
7. Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
8. Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimat proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
9. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
10. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;312:932-6.
11. Kornowski R, Mintz GS, Kent KM et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997;95:1366-9.
12. Roffi M, Moliterno DJ, Meier B et al. Impact of different platelet glycoprotein iib/iiia receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention. Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up. Circulation 2002;105:2730-6.
13. King SB 3rd, Kosinski AS, Guyton RA et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000;35:1116-21.
14. Suzuki T, Kopia G, Hayashi S et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
15. Moses J W, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
16. Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIa inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477-84.